NEW YORK – Startup RenalytixAI has partnered with Mount Sinai Health System to launch a clinical study to analyze biomarkers that may predict major adverse kidney events in patients hospitalized with COVID-19.
London-based RenalytixAI believes the multi-part stratification study will help advance commercialization of its KidneyIntelX blood-based assay for acute and chronic kidney disease (CKD) detection.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
